Does Rallies show Form 4 insider transactions for NKTR?

Yes. Rallies tracks NKTR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NKTR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.

NKTR (Nektar Therapeutics) Stock Analysis - Insider Trades

Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of May 21, 2026, NKTR trades at $69.51 with a market cap of $2.31B and a P/E ratio of -8.33. NKTR moved +2.89% today. Year to date, NKTR is +56.26%; over the trailing twelve months it is +574.24%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is strong buy with an average price target of $153.71. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NKTR stock inside the company?

Recent NKTR insider activity includes Zalevsky Jonathan sold 180, ROBIN HOWARD W sold 423, Zalevsky Jonathan sold 3.87K, Zalevsky Jonathan sold 1.16K, and Wilson Mark Andrew sold 630. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NKTR Key Metrics

Key financial metrics for NKTR
Metric	Value
Price	$69.51
Market Cap	$2.31B
P/E Ratio	-8.33
EPS	$-8.23
Dividend Yield	0.00%
52-Week High	$109.00
52-Week Low	$6.48
Volume	8
Avg Volume	0
Revenue (TTM)	$55.63M
Net Income	$-158.10M
Gross Margin	0.00%

Recent NKTR Insider Trades

Zalevsky Jonathan sold 180 (~$13.14K) on Feb 18, 2026.
ROBIN HOWARD W sold 423 (~$30.88K) on Feb 18, 2026.
Zalevsky Jonathan sold 3.87K (~$137.94K) on Jan 20, 2026.
Zalevsky Jonathan sold 1.16K (~$62.80K) on Nov 25, 2025.
Wilson Mark Andrew sold 630 (~$34.20K) on Nov 25, 2025.

Latest NKTR News

Nektar Therapeutics closes $373.8 M offering, reports $44.9 M Q1 net loss, advances Phase 3 — May 7, 2026
Nektar Therapeutics Sells 4.06M Shares at $92 to Raise $373.8M — Apr 23, 2026
Nektar Gains 18% After Alopecia Trial Win and $250M Offering — Apr 21, 2026
Nektar Therapeutics posts 26-28% alopecia trial response, shares surge 21.5%, PT to $185 — Apr 20, 2026
Rezpegaldesleukin Shows Broad EASI Efficacy, 28.2% SALT Reduction And Q2 2026 Phase 3 Start — Mar 28, 2026

NKTR Analyst Consensus

9 analysts cover NKTR: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $153.71.

Common questions about NKTR

Who is trading NKTR stock inside the company?: Recent NKTR insider activity includes Zalevsky Jonathan sold 180, ROBIN HOWARD W sold 423, Zalevsky Jonathan sold 3.87K, Zalevsky Jonathan sold 1.16K, and Wilson Mark Andrew sold 630. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NKTR?: Yes. Rallies tracks NKTR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NKTR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.